8-K: Clorox Acquires PURELL Maker GOJO for $2.25 Billion

Clorox expands its health and hygiene portfolio by acquiring GOJO Industries, makers of PURELL, for $2.25 billion in cash, including tax benefits.

Summary

• Clorox entered into a definitive agreement to acquire GOJO Industries, Inc., maker of PURELL, for $2.25 billion in cash.
• The purchase price includes anticipated tax benefits valued at approximately $330 million, resulting in a net purchase price of $1.92 billion.
• GOJO Industries has nearly $800 million in annual sales and has delivered mid-single-digit growth with a three-year CAGR of 5%.
• Over 80% of GOJO's revenue comes from B2B distributors, supported by approximately 20 million soap and sanitizer dispensers.
• The PURELL brand holds the #1 market share position in hand sanitizer across both B2B and retail channels.
• Clorox plans to fund the transaction primarily through debt financing.
• The transaction is subject to regulatory approval and other customary closing conditions and is expected to be completed before the end of Clorox's Fiscal Year 2026.
• Clorox reaffirms its fiscal year 2026 outlook for net sales, diluted EPS, and adjusted EPS, as previously guided to the lower end of the range on November 3, 2025.

Sentiment

Score: 8

Explanation: The acquisition of GOJO Industries is a strategic move that significantly expands Clorox's presence in the growing health and hygiene market. The PURELL brand's strong market position, recurring revenue, and expected synergies, coupled with Clorox's reaffirmed fiscal year outlook, indicate a positive long-term outlook despite initial neutrality to EPS and EBITDA margins in the first year due to integration and debt financing.

Positives

• Expands Clorox's position in health and hygiene to include skin hygiene, diversifying its portfolio.
• Acquisition is growth accretive and advances Clorox's IGNITE strategy.
• GOJO has nearly $800 million in annual sales with a history of mid-single-digit growth and a 5% three-year CAGR.
• PURELL holds the #1 market share in hand sanitizer across both B2B and retail channels.
• Provides exposure to sizeable and growing categories with favorable macro and consumer tailwinds.
• Expected to accelerate PURELL's growth opportunities in retail through Clorox's brand-building, innovation, and distribution capabilities.
• Combines GOJO's commercial, manufacturing, R&D, and regulatory capabilities with Clorox's strengths to create a best-in-class B2B platform.
• Expected to generate at least $50 million in run-rate cost synergies.
• Accretive to Clorox's adjusted EBITDA margins after realization of run-rate cost synergies (neutral in the first year).
• Accretive to Clorox's adjusted EPS in the second year (neutral in the first year).
• Contributes a recurring revenue and stable earnings base to Clorox.
• Supports Clorox's long-term sales growth target of 3-5%.
• Cultural and organizational compatibility with a strong management team and talent.

Negatives

• The transaction will be primarily funded through debt financing, which will increase Clorox's indebtedness.
• The acquisition is expected to be neutral to adjusted EPS in the first year.
• The acquisition is expected to be neutral to adjusted EBITDA margins in the first year.

Risks

• Occurrence of any event, change, or circumstance that could lead to the termination of the GOJO acquisition agreement.
• Risk that conditions to completion (including regulatory approval) are not satisfied in a timely manner or at all.
• Risks arising from the integration of the GOJO business.
• Uncertainty of rating agency actions following the acquisition.
• Risk that anticipated benefits and synergies may not be realized when expected or at all.
• Risk that the proposed acquisition may not be completed in a timely manner or at all.
• Risk of unexpected costs or expenses resulting from the proposed acquisition.
• Risk of litigation related to the proposed acquisition, including resulting expense or delay.
• Risks related to disruption to ongoing business operations of Clorox and GOJO and diversion of management time.
• Risk that the proposed acquisition may adversely affect the ability of Clorox and GOJO to retain key personnel, customers, and suppliers.
• Risk that Clorox's credit ratings decline following the proposed acquisition.
• Risk that the announcement or consummation of the proposed acquisition has a negative effect on Clorox's common stock market price or on Clorox's or GOJO's operating results.
• Unfavorable general economic and geopolitical conditions, including inflation, supply chain disruptions, labor shortages, wage pressures, fuel and energy costs, interest rate fluctuations, foreign currency exchange rate fluctuations, weather events, natural disasters, disease outbreaks, pandemics, terrorism, and unstable geopolitical conditions.
• Impact of market and category declines, and product/geographic mix on sales growth targets.
• Ability to successfully execute or realize anticipated benefits of strategic or transformational initiatives, including the ERP transition.
• Impact of changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences.
• Intense competition in Clorox's markets.
• Volatility and increases in the costs of raw materials, energy, transportation, labor, and other necessary supplies or services.
• Risks related to supply chain issues, product shortages, and disruptions to the business, as a result of increased supply chain dependencies due to an expanded supplier network and a reliance on certain single-source suppliers.
• Risks related to Clorox's use of and reliance on information technology systems, including potential and actual security breaches, cyberattacks, privacy breaches or data breaches.
• The ability of Clorox to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries.
• The ability of Clorox to successfully manage global political, legal, tax and regulatory risks, including due to regulatory uncertainty and lack of regulatory convergence among different jurisdictions.
• Lower revenue, increased costs, other financial statement impacts or reputational harm resulting from government actions, compliance with regulations, or any material costs imposed by changes in regulation.
• Clorox's ability to maintain its business reputation and the reputation of its brands and products.
• Dependence on key customers and risks related to customer consolidation and ordering patterns.
• Clorox's ability to attract and retain key personnel, which may continue to be impacted by challenges in the labor market.
• Changes to Clorox's processes and procedures as a result of its digital capabilities and productivity enhancements that may result in changes to internal controls over financial reporting.
• Risks related to the acquisition of The Procter & Gamble Company's interest in the Glad business.
• Risks related to international operations and international trade, including changing macroeconomic conditions, foreign currency fluctuations, changes in governmental policies, labor claims and civil unrest, and potential operational or supply chain disruptions from wars and military conflicts.
• Potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach.
• Widespread health emergencies.
• The possibility of nationalization, expropriation of assets or other government action or inaction, including the impacts of a prolonged U.S. government shutdown.
• The impact of climate change and other sustainability issues on sales, operating costs, reputation or stakeholder relationships.
• The impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls.
• Risks relating to acquisitions, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks and goodwill.
• The accuracy of Clorox's estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based.
• Risks related to Clorox's reliance on third-party service providers, including inability to meet cost savings or efficiencies, business or systems disruptions, and other liabilities.
• Environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances.
• Clorox's ability to effectively utilize, assert and defend its intellectual property rights, and any infringement or claimed infringement by Clorox of third-party intellectual property rights.
• The effect of Clorox's indebtedness and credit rating on its business operations and financial results and its ability to access capital markets and other funding sources, as well as the cost of capital to Clorox.
• Clorox's ability to pay and declare dividends or repurchase its stock in the future.
• The impacts of potential stockholder activism.

Future Outlook

Clorox reaffirms its fiscal year 2026 outlook for net sales, diluted EPS, and adjusted EPS, previously guided to the lower end of the range. The acquisition is expected to be neutral to adjusted EBITDA margins and adjusted EPS in the first year, becoming accretive in the second year and beyond, contributing to Clorox's long-term sales growth target of 3-5%. The company anticipates at least $50 million in run-rate cost synergies.

Management Comments

• "This is a compelling acquisition that evolves our portfolio and scales our fastest growing, most profitable operating segment Health and Wellness as we execute our IGNITE strategy to deliver long-term shareholder value." Linda Rendle, Chair and CEO of The Clorox Company.
• "GOJO and Clorox are united by our shared commitment to make the world a cleaner and healthier place. I have long admired Clorox's ability to create great consumer brands and products that are beloved in households around the world. Clorox brings world-class consumer expertise, and they have the resources to accelerate our growth in retail channels." Carey Jaros, President and CEO of GOJO Industries.
• "Our plans for the year remain on track, and we're confirming our top and bottom-line outlook. We remain laser-focused on executing our back half plans, supported by a strong pipeline of innovation and a robust demand-creation plan. Given the complementary business, operations and culture of GOJO Industries, we are excited to seamlessly integrate this acquisition while staying on track to achieve our strategic and financial priorities." Linda Rendle.

Industry Context

The acquisition of GOJO Industries, a leader in skin health and hygiene with its PURELL brand, positions Clorox to capitalize on growing consumer and B2B demand for hygiene solutions. This move strengthens Clorox's presence in the health and wellness segment, aligning with broader industry trends emphasizing personal and public health, especially post-pandemic. It allows Clorox to leverage its consumer brand-building expertise to expand PURELL's retail presence while integrating GOJO's strong B2B network to bolster Clorox's professional business, creating a more diversified and resilient portfolio in the competitive consumer packaged goods and institutional hygiene markets.

Stakeholder Impact

• Shareholders: Expected long-term value creation through portfolio evolution, growth accretion, and synergies; potential for increased indebtedness and initial neutrality to EPS/EBITDA.
• Employees: GOJO will continue to be based in Ohio, suggesting continuity for GOJO employees; potential for integration-related changes.
• Customers: Expanded portfolio of health and hygiene solutions; enhanced distribution and innovation for PURELL brand.
• Suppliers: Potential for changes in supply chain dynamics due to integration.
• Creditors: Increased debt financing will impact Clorox's credit profile.

Next Steps

• Complete the transaction before the end of Clorox's Fiscal Year 2026, subject to regulatory approval and other customary closing conditions.
• Clorox will host a live Q&A audio webcast for analysts on February 3 to discuss second-quarter financial results.
• Strategic integration of GOJO business to ensure combined benefits.

Key Dates

Recommendation

The acquisition of GOJO Industries, a market leader with strong brand equity in PURELL, represents a strategic and accretive move for Clorox. It diversifies Clorox's portfolio into the high-growth skin health and hygiene segment, leveraging both consumer and B2B channels. The expected $50 million in run-rate cost synergies and the long-term EPS and EBITDA accretion, despite initial neutrality, signal a positive financial trajectory. While debt financing increases leverage, the strong market position of GOJO and the strategic alignment with Clorox's IGNITE strategy suggest significant long-term value creation, making it an attractive investment for growth-oriented portfolios.

Keywords

Clorox, GOJO Industries, PURELL, acquisition, merger, health and hygiene, consumer goods, B2B, hand sanitizer, debt financing, regulatory approval, fiscal year 2026 outlook, IGNITE strategy, synergies, adjusted EPS, adjusted EBITDA, consumer brands, professional business